Orion has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family
ORION CORPORATION STOCK EXCHANGE RELEASE 21 MARCH 2013 at 6.25 p.m. EET
Orion Corporation has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family in Europe. Orion applies for approval in European Union through decentralised procedure. The review process will commence once all involved member states have validated the application.
| Timo Lappalainen|
President and CEO
| Reijo Salonen|
SVP, Research and Development
Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.